Search clinical trials for: Rosiglitazone insulin sensitizing agent

Total 2909 results

St. Luke's-Roosevelt Hospital Center

Completed

Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance

HIV Infections | Obesity | Insulin Resistance

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes

Congestive Heart Failure

United States
Sanofi

Completed

Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Terminated

Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Netherlands, Austria, Spain, France, Germany, Ireland, Switzerland, Finland
GlaxoSmithKline

Completed

A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

China
J JESUS VENEGAS, MD
Instituto Mexicano del Seguro Social; National Council of Science and Technology...

Completed

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

Insulin Resistance
Novo Nordisk A/S

Terminated

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

India, Macedonia, The Former Yugoslav Republic of, Russian Federation, Turkey, Croatia, Australia, Philippines
Novo Nordisk A/S

Terminated

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
China Medical University Hospital

Completed

Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy

Type 2 Diabetes Mellitus With Features of Insulin Resistance

Taiwan
Odense University Hospital

Completed

South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus (SDDS)

Type 2 Diabetes Mellitus

Denmark
Solvay Pharmaceuticals

Completed

A Methodological Study To Evaluate The Effects of Single Oral Doses Of Pioglitazone 45 mg And Rosiglitazone 8 mg On Sodium Balance In Healthy Male Volunteers

Type 2 Diabetes Mellitus

United Kingdom
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Sanofi

Completed

Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes (SPIRIT)

Type 2 Diabetes Mellitus

Ukraine
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Austria, Switzerland, United Kingdom, Germany, Ireland
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Centre Hospitalier Universitaire Dijon

Completed

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Type 2 Diabetes

France
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

Diabetes Mellitus, Type 2 | Diabetes

United Arab Emirates, Malaysia, India, South Africa, Algeria, Lebanon
Novo Nordisk A/S

Completed

Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark, Sweden, Norway
CPEX Pharmaceuticals Inc.

Completed

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus (CPEX-011)

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Egypt
Novo Nordisk A/S

Completed

Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes

Italy
Ain Shams University

Completed

A Clinical Study for the Effect of 4th Generation Poly AmidoAmine Dendrimer on Post-Bleaching Hypersensitivity and Shade Stability

Tooth Hypersensitivity

Egypt
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

China
GlaxoSmithKline

Completed

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

Neuropathy, Diabetic

Netherlands
Medstar Health Research Institute
GlaxoSmithKline

Terminated

Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS

Metabolic Syndrome

United States
Baskent University

Completed

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Obesity | Type 2 Diabetes Mellitus

Turkey
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (PreFER)

Diabetes Mellitus, Type 2 | Diabetes

Austria, Germany, Switzerland
Novo Nordisk A/S

Completed

Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland, Spain, Germany, Finland, France
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Denmark
IKFE Institute for Clinical Research and Development

Completed

Effect of Insulin Glulisine vs Regular Human Insulin on Postprandial Endothelial Function in Type 2 Diabetes

Diabetes Mellitus

Germany
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Two Formulations of Biphasic Insulin Aspart 70

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
CPEX Pharmaceuticals Inc.

Withdrawn

Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

Type 1 Diabetes Mellitus
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Japan
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Rosiglitazone in Treating Patients With Liposarcoma

Sarcoma

United States
Jonsson Comprehensive Cancer Center
National Institutes of Health (NIH)

Terminated

Rosiglitazone in Treating Patients With Pituitary Tumors

Brain and Central Nervous System Tumors

United States
GlaxoSmithKline

Terminated

Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

Alzheimer's Disease

Australia, Spain, United States, Bulgaria, Germany, Belgium, Canada, Hong Kong, Korea, Republic of, Portugal, Argentina, Chile, Greece, Slovenia, Czechia, France, Hungary, Italy, South Africa, India, Sweden, Netherlands, Philippines, ... and more
Stanford University

Terminated

Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

Dilated Cardiomyopathy

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Head and Neck Cancer

United States
Novo Nordisk A/S

Completed

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

United Kingdom, France, Netherlands, Belgium, Ireland

Search clinical trials for: Rosiglitazone insulin sensitizing agent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations